Global Retirement Partners LLC Purchases New Stake in Boston Scientific Corporation $BSX

Global Retirement Partners LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel reports. The fund bought 37,710 shares of the medical equipment provider’s stock, valued at approximately $1,609,000.

A number of other institutional investors and hedge funds also recently modified their holdings of BSX. Vanguard Group Inc. grew its stake in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after buying an additional 1,436,550 shares during the last quarter. State Street Corp lifted its stake in Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after buying an additional 920,495 shares during the last quarter. Capital World Investors boosted its holdings in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after acquiring an additional 502,627 shares during the period. Norges Bank acquired a new position in shares of Boston Scientific during the fourth quarter valued at $2,199,395,000. Finally, Morgan Stanley grew its position in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BSX. Evercore set a $65.00 target price on shares of Boston Scientific in a research note on Monday, July 6th. UBS Group cut their price target on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Jefferies Financial Group reduced their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Wells Fargo & Company lowered their target price on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 30th. Finally, Needham & Company LLC cut their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 202,122 shares of company stock valued at $9,813,931 in the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Price Performance

NYSE BSX opened at $51.46 on Tuesday. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The firm has a market capitalization of $74.58 billion, a PE ratio of 20.83, a P/E/G ratio of 1.13 and a beta of 0.56. The company’s 50 day simple moving average is $46.12 and its 200 day simple moving average is $58.81. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $0.75 EPS. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.